Linked Life Data

19794409

Source:http://linkedlifedata.com/resource/pubmed/id/19794409

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19794409rdf:typepubmed:Citationlld:pubmed
pubmed-article:19794409lifeskim:mentionsumls-concept:C0009319lld:lifeskim
pubmed-article:19794409lifeskim:mentionsumls-concept:C0226896lld:lifeskim
pubmed-article:19794409lifeskim:mentionsumls-concept:C0205531lld:lifeskim
pubmed-article:19794409lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:19794409lifeskim:mentionsumls-concept:C1527415lld:lifeskim
pubmed-article:19794409lifeskim:mentionsumls-concept:C1327616lld:lifeskim
pubmed-article:19794409lifeskim:mentionsumls-concept:C1521801lld:lifeskim
pubmed-article:19794409lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:19794409pubmed:issue1lld:pubmed
pubmed-article:19794409pubmed:dateCreated2009-12-17lld:pubmed
pubmed-article:19794409pubmed:abstractTextInflammatory bowel disease (IBD) is a chronic inflammatory gastrointestinal disorder. Systemic treatment of IBD patients with anti-tumor necrosis factor (TNF)-alpha antibodies has proven to be a highly promising approach, but several drawbacks remain, including side effects related to systemic administration and high cost of treatment. Lactococcus lactis was engineered to secrete monovalent and bivalent murine (m)TNF-neutralizing Nanobodies as therapeutic proteins. These therapeutic proteins are derived from fragments of heavy-chain camelid antibodies and are more stable than conventional antibodies. L. lactis-secreted anti-mTNF Nanobodies neutralized mTNF in vitro. Daily oral administration of Nanobody-secreting L. lactis resulted in local delivery of anti-mTNF Nanobodies at the colon and significantly reduced inflammation in mice with dextran sulfate sodium (DSS)-induced chronic colitis. In addition, this approach was also successful in improving established enterocolitis in interleukin 10 (IL10)(-/-) mice. Finally, L. lactis-secreted anti-mTNF Nanobodies did not interfere with systemic Salmonella infection in colitic IL10(-/-) mice.In conclusion, this report details a new therapeutic approach for treatment of chronic colitis, involving in situ secretion of anti-mTNF Nanobodies by orally administered L. lactis bacteria. Therapeutic application of these engineered bacteria could eventually lead to more effective and safer management of IBD in humans.lld:pubmed
pubmed-article:19794409pubmed:languageenglld:pubmed
pubmed-article:19794409pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19794409pubmed:citationSubsetIMlld:pubmed
pubmed-article:19794409pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19794409pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19794409pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19794409pubmed:statusMEDLINElld:pubmed
pubmed-article:19794409pubmed:monthJanlld:pubmed
pubmed-article:19794409pubmed:issn1935-3456lld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:CuvelierCClld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:RemautEElld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:DreierTTlld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:LauwereysMMlld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:de HaardHHlld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:Van HuysseJJlld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:BeirnaertEElld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:SteidlerLLlld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:RottiersPPlld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:DemetterPPlld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:Vandenbroucke...lld:pubmed
pubmed-article:19794409pubmed:authorpubmed-author:HuyckLLlld:pubmed
pubmed-article:19794409pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19794409pubmed:volume3lld:pubmed
pubmed-article:19794409pubmed:ownerNLMlld:pubmed
pubmed-article:19794409pubmed:authorsCompleteYlld:pubmed
pubmed-article:19794409pubmed:pagination49-56lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:meshHeadingpubmed-meshheading:19794409...lld:pubmed
pubmed-article:19794409pubmed:year2010lld:pubmed
pubmed-article:19794409pubmed:articleTitleOrally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis.lld:pubmed
pubmed-article:19794409pubmed:affiliationDepartment for Molecular Biomedical Research, VIB, Zwijnaarde, Belgium.lld:pubmed
pubmed-article:19794409pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19794409pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19794409lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:19794409lld:pubmed